JBIO advances JADE101 in IgA nephropathy toward phase II and III
JBIO is progressing three autoimmune-disease assets. JADE101 posted strong phase I results in IgA nephropathy and is moving into phase II and III, supported by differentiation on potency, dosing convenience and safety.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.